Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Minerva Neurosciences (NERV) Common Equity (2016 - 2026)

Minerva Neurosciences filings provide 3 years of Common Equity readings, the most recent being $8.0 million for Q4 2021.

  • On a quarterly basis, Common Equity fell 84.86% to $8.0 million in Q4 2021 year-over-year; TTM through Dec 2021 was $8.0 million, a 84.86% decrease, with the full-year FY2021 number at $8.0 million, down 84.86% from a year prior.
  • Common Equity hit $8.0 million in Q4 2021 for Minerva Neurosciences, down from $28.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $58.0 million in Q3 2020 to a low of $8.0 million in Q4 2021.
  • Median Common Equity over the past 3 years was $36.2 million (2021), compared with a mean of $36.8 million.
  • The widest YoY moves for Common Equity: up 143.63% in 2021, down 84.86% in 2021.
  • Minerva Neurosciences' Common Equity stood at $27.8 million in 2019, then soared by 89.57% to $52.7 million in 2020, then tumbled by 84.86% to $8.0 million in 2021.
  • The last three reported values for Common Equity were $8.0 million (Q4 2021), $28.1 million (Q3 2021), and $36.2 million (Q2 2021) per Business Quant data.